Domača stranJAZZ • NASDAQ
add
Jazz Pharmaceuticals PLC
101,55 $
Po zaprtju:(0,00 %)0,00
101,55 $
Konec trgovanja: 16. apr., 16:35:21 GMT -4 · USD · NASDAQ · Izjava
Prejšnji trg. dan.
102,91 $
Dnevni razpon
100,42 $ - 103,96 $
Letni razpon
95,49 $ - 148,06 $
Tržna kapitalizacija
6,17 mrd. USD
Povprečni obseg
1,43 mio.
Razm. P/E
11,74
Dividendna donosnost
-
Primarna borza
NASDAQ
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | dec. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 1,09 mrd. | 7,53 % |
Stroški poslovanja | 768,69 mio. | 9,42 % |
Čisti dohodek | 191,12 mio. | 102,98 % |
Čista dobičkovnost prihodkov | 17,56 | 88,82 % |
Earnings per share | 6,60 | 31,47 % |
EBITDA | 396,98 mio. | 0,82 % |
Efektivna davčna stopnja | −43,48 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | dec. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 2,99 mrd. | 83,66 % |
Skupna sredstva | 12,01 mrd. | 5,43 % |
Skupne obveznosti | 7,92 mrd. | 3,42 % |
Celoten lastniški kapital | 4,09 mrd. | — |
Shares outstanding | 60,73 mio. | — |
Razmerje P/B | 1,52 | — |
Donosnost sredstev | 4,71 % | — |
Donosnost kapitala | 5,54 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | dec. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 191,12 mio. | 102,98 % |
Denar iz dejavnosti | 398,58 mio. | 138,19 % |
Denar iz naložb | −193,29 mio. | −289,87 % |
Denar iz financiranja | −8,28 mio. | 91,75 % |
Neto sprememba denarnih sredstev | 194,73 mio. | 14,13 % |
Prost denarni tok | 466,32 mio. | 470,30 % |
Vizitka
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
Generalni direktor
Datum ustanovitve
2003
Spletno mesto
Zaposleni
2.800
